ALLIANCES AND COLLABORATIONS (Tables)

9 Months Ended

Sep. 30, 2011

Sanofi [Member]

Alliances and Collaborations Statement [Line Items]

Summarized Financial Information Reflected In Consolidated Financial Statements [Text Block]

		Three Months Ended September 30,				Nine Months Ended September 30,
Dollars in Millions		2011			2010	2011			2010
Territory covering the Americas and Australia:
	Net sales	$	1,936	$	1,874	$	5,959	$	5,580
	Discovery royalty expense		368		337		1,123		998
	Noncontrolling interest – pre-tax		590		523		1,764		1,543
	Profit distributions to Sanofi		(523)		(545)		(1,824)		(1,598)
Territory covering Europe and Asia:
	Equity in net income of affiliates		(75)		(73)		(226)		(261)
	Profit distributions to the Company		97		85		224		239
Other:
	Net sales in Europe comarketing countries and other		68		87		213		295
	Amortization (income)/expense – irbesartan license fee		(7)		(7)		(23)		(23)
	Supply activities and development and opt-out royalty
	(income)/expense		6		3		21		(28)
						September 30,		December 31,
Dollars in Millions						2011		2010
Investment in affiliates – territory covering Europe and Asia						$	24	$	22
Deferred income – irbesartan license fee							37		60

Sanofi [Member] | Territory Covering Europe and Asia [Member]

Alliances and Collaborations Statement [Line Items]

Equity Method Investments Disclosure [Text Block]

	Three Months Ended September 30,				Nine Months Ended September 30,
Dollars in Millions	2011		2010		2011		2010
Net sales	$	364	$	417	$	1,125	$	1,465
Gross profit		161		174		501		662
Net income		131		141		413		528

Otsuka [Member]

Alliances and Collaborations Statement [Line Items]

Summarized Financial Information Reflected In Consolidated Financial Statements [Text Block]

		Three Months Ended September 30,				Nine Months Ended September 30,
Dollars in Millions		2011		2010		2011		2010
ABILIFY* net sales, including amortization of extension payment		$	691	$	608	$	2,021	$	1,858
Oncology Products collaboration fee expense			30		30		100		92
Reimbursement of operating expenses to/(from) Otsuka			(23)		(26)		(68)		(74)
Amortization (income)/expense – extension payment			16		17		49		49
Amortization (income)/expense – upfront, milestone and other
	licensing payments		1		1		5		5
						September 30,		December 31,
Dollars in Millions						2011		2010
Other assets - extension payment						$	236	$	285
Other intangible assets - upfront, milestone and other licensing payments							6		11

Lilly [Member]

Alliances and Collaborations Statement [Line Items]

Summarized Financial Information Reflected In Consolidated Financial Statements [Text Block]

		Three Months Ended September 30,				Nine Months Ended September 30,
Dollars in Millions		2011		2010		2011		2010
Net sales		$	172	$	159	$	510	$	497
Distribution fees and royalty expense			72		62		212		194
Research and development expense reimbursement to Lilly – necitumumab			4		4		10		9
Amortization (income)/expense – upfront, milestone and other
	licensing payments		9		9		28		28
Japan commercialization fee (income)/expense			(9)		(11)		(24)		(30)
						September 30,		December 31,
Dollars in Millions						2011		2010
Other intangible assets – upfront, milestone and other licensing payments						$	258	$	286

Gilead [Member]

Alliances and Collaborations Statement [Line Items]

Summarized Financial Information Reflected In Consolidated Financial Statements [Text Block]

	Three Months Ended September 30,				Nine Months Ended September 30,
Dollars in Millions	2011		2010		2011		2010
Net sales	$	289	$	264	$	858	$	769
Equity in net loss of affiliates		3		3		11		9

AstraZeneca [Member]

Alliances and Collaborations Statement [Line Items]

Summarized Financial Information Reflected In Consolidated Financial Statements [Text Block]

		Three Months Ended September 30,				Nine Months Ended September 30,
Dollars in Millions		2011		2010		2011		2010
Net sales		$	127	$	47	$	320	$	85
Profit sharing expense			58		21		148		39
Commercialization expense reimbursements to/(from) AstraZeneca			(11)		(13)		(30)		(25)
Research and development expense reimbursements to/(from) AstraZeneca			4		6		33		9
Amortization (income)/expense – upfront, milestone and other
	licensing payments		(10)		(7)		(28)		(20)
						September 30,		December 31,
Dollars in Millions						2011		2010
Deferred income – upfront, milestone and other licensing payments						$	382	$	290

Pfizer [Member]

Alliances and Collaborations Statement [Line Items]

Summarized Financial Information Reflected In Consolidated Financial Statements [Text Block]

		Three Months Ended September 30,				Nine Months Ended September 30,
Dollars in Millions		2011		2010		2011		2010
Commercialization expense reimbursement to/(from) Pfizer		$	(2)	$	(2)	$	(5)	$	(4)
Research and development reimbursements to/(from) Pfizer			(16)		(39)		(74)		(158)
Amortization (income)/expense – upfront, milestone and other
	licensing payments		(8)		(8)		(24)		(24)
						September 30,		December 31,
Dollars in Millions						2011		2010
Deferred income – upfront, milestone and other licensing payments						$	358	$	382